Alteration in Mean Platelet Volume and Platicrit Values in Patients With Cancer That Developed Thrombosis

被引：47

作者：

Mutlu, Hasan ^{[1
]}

Artis, Tarik A. ^{[2
]}

Erden, Abduelsamet ^{[3
]}

Akca, Zeki ^{[4
]}

机构：

[1] Kayseri Training & Res Hosp, Dept Med Oncol, Kayseri, Turkey

[2] Erciyes Univ, Dept Gen Surg, Fac Med, Kayseri, Turkey

[3] Kayseri Training & Res Hosp, Dept Internal Med, Kayseri, Turkey

[4] Mersin Govt Hosp, Dept Radiat Oncol, Mersin, Turkey

来源：

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS | 2013年 / 19卷 / 03期

关键词：

deep venous thrombosis; thrombosis; thrombosis prophylaxis; ARTERIAL THROMBOEMBOLIC EVENTS; RISK; ANGIOGENESIS; MORTALITY; DISEASE; SIZE;

D O I：

10.1177/1076029611433644

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Mean platelet volume (MPV) is an indicator of thrombocyte volume and tendency to thrombosis can be mentioned in case of MPV elevation. Cancers are one of the important groups of thrombotic diseases. In the present study, MPV value was scrutinized in patients with cancer that developed thrombosis. Totally 43 patients followed in Kayseri Training and Research Hospital, in who thromboembolus has been developed, were prospectively recruited in the study. Thrombocyte, MPV, and platicrit (PCT) values were recorded at the time of cancer diagnosis and thrombosis development. Frequency analysis, crosstabs, and paired samples t test were used. Analyses showed that MPV values at the time of thrombosis development were significantly low as compared to those at the time of cancer diagnosis (P = .041). Thrombocyte count and PCT values were also low but not significant. The result of the present study is likely to show that thrombocytes have ignorable effect on thrombosis development in patients with cancer.

引用

页码：331 / 333

页数：3

共 21 条

[11] Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy - Risk analysis using Medicare claims data
Levitan, N
Dowlati, A
Remick, SC
Tahsildar, HI
Sivinski, LD
Beyth, R
Rimm, AA
[J]. MEDICINE, 1999, 78 (05) : 285 - 291
[12] Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?
Maraveyas, A.
Johnson, M.
[J]. BRITISH JOURNAL OF CANCER, 2009, 100 (12) : 1837 - 1841
[13] PLATELET SIZE IN STROKE PATIENTS
OMALLEY, T
LANGHORNE, P
ELTON, RA
STEWART, C
[J]. STROKE, 1995, 26 (06) : 995 - 999
[14] Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials
Ranpura, Vishal
Hapani, Sanjaykumar
Chuang, Jeff
Wu, Shenhong
[J]. ACTA ONCOLOGICA, 2010, 49 (03) : 287 - 297
[15] Mechanisms of disease - Atherosclerosis - An inflammatory disease
Ross, R
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (02) : 115 - 126
[16] Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
Scappaticci, Frank A.
Skillings, Jamey R.
Holden, Scott N.
Gerber, Hans-Peter
Miller, Kathy
Kabbinavar, Fairooz
Bergsland, Emily
Ngai, James
Holmgren, Eric
Wang, Jiuzhou
Hurwitz, Herbert
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (16): : 1232 - 1239
[17] Platelets and stroke
Smith, NM
Pathansali, R
Bath, PMW
[J]. VASCULAR MEDICINE, 1999, 4 (03) : 165 - 172
[18] Anticoagulation in the management of venous thromboembolism in the cancer patient
Streiff, Michael B.
[J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2011, 31 (03) : 282 - 294
[19] LARGE PLATELETS CIRCULATE IN AN ACTIVATED STATE IN DIABETES-MELLITUS
TSCHOEPE, D
ROESEN, P
ESSER, J
SCHWIPPERT, B
NIEUWENHUIS, HK
KEHREL, B
GRIES, FA
[J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1991, 17 (04) : 433 - 438
[20] Turhan O, 2010, MED SCI MONITOR, V16, pCR202

← 1 2 3 →